Search

Displaying results 3341 - 3350 of 5449 in total
  1. Drug

    AdPEDF

    go.drugbank.com/drugs/DB05138
    Experimental

    AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). … It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal blood vessels to regress while protecting the eye’s photoreceptors

  2. Drug

    Mepivacaine

    go.drugbank.com/drugs/DB00961
    ApprovedInvestigationalVet approved

    It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route.

    Mixtures: MEPISEAL-EProducts: MEPIVASTESIN INJECTION 30 mg/ml, Mepivacain Accord 10 mg/ml Injektionslösung
  3. Drug

    Diosmetin

    go.drugbank.com/drugs/DB11259
    Approved

    It also acts as a weak TrkB receptor agonist [A27230].

  4. Drug

    Cinnamaldehyde

    go.drugbank.com/drugs/DB14184
    Approved

    It occurs naturally in the bark of cinnamon trees and other species of the genus Cinnamomum such as camphor and cassia. Sensitivity to cinnamaldehyde may be identified with a clinical patch test.

    Synonyms: (E)-3-Phenylpropenal, (E)-3-Phenyl-propenal
  5. Drug

    Autologous peripheral blood-derived CD34+ cells

    go.drugbank.com/drugs/DB16367
    ApprovedInvestigational

    [L27741] It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).

  6. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

  7. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    [A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. … [L13290] It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.

    Products: DARZALEX 20 MG/ML, DARZALEX® SC 120 MG/ML SOLUCIÓN INYECTABLE
  8. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant.

  9. Drug

    Interferon alfa-2b

    go.drugbank.com/drugs/DB00105
    ApprovedInvestigational

    It is used extensively as an antiviral or antineoplastic agent.

    Products: BETAFERON 0.3 MG LIYOFILIZE TOZ ICEREN FLAKON + KULLANIMA HAZIR ENJEKTORDE COZUCU, 12 ADET, BETAFERON 0.3 MG LIYOFILIZE TOZ ICEREN FLAKON + KULLANIMA HAZIR ENJEKTORDE COZUCU, 45 ADET
  10. Drug

    Dalfopristin

    go.drugbank.com/drugs/DB01764
    Approved

    It is not effective against Enterococcus faecalis infections.